Market Research Logo

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

Summary

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have T2DM.

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Scope

The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.

  • What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
  • Which classes of novel drugs are most prominent within the pipeline?
  • Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%.
  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion.
  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
Reasons to buy

This report will enable you to -
  • Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
  • Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.


Newer Therapies Will Steer Type 2 Diabetes Market in South-East Asia to $2.7 Billion by 2022, says GBI Research

The South-East Asian Type 2 Diabetes Mellitus (T2DM) market, which includes South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, will rise from $1.7 billion in 2015 to $2.7 billion by 2022, at a compound annual growth rate of 7.1%, according to business intelligence provider GBI Research.

The company’s latest report* states that as well as the rapidly expanding prevalence population in South-East Asia, market growth will be driven by the increased uptake of recently approved and emerging branded T2DM therapeutics, in favor of lower-cost generic products.

Aswini Nath, Analyst for GBI Research, explains: “Unmet needs relating to patient convenience and ease of use will be addressed significantly over the forecast period. Higher levels of innovation are apparent in the early-stage pipeline, which may lead to considerable improvements beyond the existing range of products, in terms of safety and efficacy in the long term.

“In terms of recently approved therapeutics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors have already achieved strong market uptake and are all expected to increase their market shares over the forecast period. In comparison with many previously marketed therapies, these new products provide improved weight control and lowered hypoglycemia risk.”

In terms of late-stage pipeline products with the potential to change the treatment paradigm, six candidates stand out as offering superior safety, efficacy, and patient compliance. These are Novo Nordisk’s NN-9535 (semaglutide subcutaneous formulation) and OG-217SC (semaglutide oral formulation) and Eli Lilly’s Trulicity (dulaglutide), which are GLP-1 receptor agonists; Merck’s ertugliflozin and Theracos's bexagliflozin, which are SGLT-2 inhibitors; and Merck’s omarigliptin, which is a DPP-4 inhibitor.

Of these products, GBI Research believes that OG-217SC, being a first-to-market oral formulation in the GLP-1 agonist class of drug, has the most potential to change the treatment paradigm due to its improved administration route compared to other drugs in the same class.

However, Nath adds: “Although increased uptake of branded drugs is expected, metformin - a low-cost generic drug - will maintain its pivotal role in the T2DM treatment algorithm in South-East Asia. Due to its well-characterized safety and efficacy profiles, wide availability and low cost, metformin will continue to be prescribed as the first-line pharmacotherapy and also remain the favored option for use in combination therapies.”

*Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

This report provides analysis of the Type 2 Diabetes Mellitus market across South-East Asia, which includes, South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia. It includes annualized market data from 2015 and forecast to 2022.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Introduction
2.2 Epidemiology
2.2.1 Asthma
2.2.2 Chronic Obstructive Pulmonary Fibrosis
2.2.3 Idiopathic Pulmonary Fibrosis
2.2.4 Cystic Fibrosis
2.3 Pathophysiology
2.3.1 Asthma
2.3.2 Chronic Obstructive Pulmonary Disease
2.3.3 Idiopathic Pulmonary Fibrosis
2.3.4 Cystic Fibrosis
2.4 Symptoms
2.5 Diagnosis
2.5.1 Asthma
2.5.2 Chronic Obstructive Pulmonary Fibrosis
2.5.3 Idiopathic Pulmonary Fibrosis
2.5.4 Cystic Fibrosis
2.6 Disease Severity and Prognosis
2.6.1 Asthma
2.6.2 Chronic Obstructive Pulmonary Fibrosis
2.6.3 Idiopathic Pulmonary Fibrosis
2.6.4 Cystic Fibrosis
2.7 Treatment
2.7.1 Asthma
2.7.2 Chronic Obstructive Pulmonary Fibrosis
2.7.3 Idiopathic Pulmonary Fibrosis
2.7.4 Cystic Fibrosis
3 Key Marketed Products
3.1 Overview
3.2 Advair - GSK
3.3 Spiriva - Boehringer Ingelheim, Pfizer
3.4 Symbicort - AstraZeneca/Astellas
3.5 Singulair (montelukast) - Merck & Co.
3.6 Flixotide/Flovent - GSK
3.7 Ventolin - GSK
3.8 Kalydeco - Vertex
3.9 Pulmozyme - Roche
3.10 Esbriet - Roche
3.11 TOBI - Novartis
3.12 Conclusion
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.5 Conclusion
5 Multi-scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 G-Protein Coupled Receptors
5.3.2 Immune/Inflammatory Mediators
5.3.3 Transcription Factors
5.3.4 Signal Transduction
5.3.5 CFTR Modulator
5.4 Assessment of Key Pipeline Products
5.4.1 Dupilumab - Regeneron Pharmaceuticals/Sanofi
5.4.2 Benralizumab - AstraZeneca/Medimmune
5.4.3 Lebrikizumab - Roche/Genentech
5.4.4 PT010 (Budesonide plus Formoterol Fumarate plus Glycopyrronium) - AstraZeneca/Pearl Therapeutics
5.4.5 Tralokinumab - AstraZeneca
5.4.6 Batefenterol - GSK/Theravance
5.4.7 Conclusion
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 GlaxoSmithKline
6.1.2 Vertex
6.1.3 AstraZeneca
6.1.4 Roche
6.1.5 Novartis
6.1.6 Boehringer Ingelheim
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deal by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type and Molecular Target
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Mechanism of Action and Value
7.2.4 Table for Co-development Deals Valued Above $100m
8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA filed/Phase 0
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.3 Abbreviations
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape
8.5 Contact Us
8.6 Disclaimer
1.1 List of Tables
Table 1: Dose Levels for Groups Initially Receiving Metformin in Combination with Glyburide, Metformin Monotherapy and Glyburide Monotherapy 26
Table 2: T2DM Therapeutics, Global, All Pipeline Products, Discovery Stage, March 2016 138
Table 3: T2DM Therapeutics, Global, All Pipeline Products, Preclinical Stage, March 2016 141
Table 4: T2DM Therapeutics, Global, All Pipeline Products, IND/CTA-filed Stage, March 2016 149
Table 5: T2DM Therapeutics, Global, All Pipeline Products, Phase I, March 2016 149
Table 6: T2DM Therapeutics, Global, All Pipeline Products, Phase II, March 2016 151
Table 7: T2DM Therapeutics, Global, All Pipeline Products, Phase III, March 2016 153
Table 8: T2DM Therapeutics, Global, All Pipeline Products, Pre-registration Stage, March 2016 154
Table 9: T2DM Therapeutics Market, South-East Asia, Market Forecast, 2015-2022 155
Table 10: T2DM Therapeutics Market, South Korea, Market Forecast, 2015-2022 155
Table 11: T2DM Therapeutics Market, Singapore, Market Forecast, 2015-2022 156
Table 12: T2DM Therapeutics Market, Taiwan, Market Forecast, 2015-2022 156
Table 13: T2DM Therapeutics Market, Malaysia, Market Forecast, 2015-2022 157
Table 14: T2DM Therapeutics Market, Philippines, Market Forecast, 2015-2022 157
Table 15: T2DM Therapeutics Market, Thailand, Market Forecast, 2015-2022 158
Table 16: T2DM Therapeutics Market, Vietnam, Market Forecast, 2015-2022 158
Table 17: T2DM Therapeutics Market, Indonesia, Market Forecast, 2015-2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report